Tuesday 5 November 2024

The Pharma Letter Podcast — Episode 14 — A vaccine for Alzheimer's?

Biotechnology
Simon Wentworth
6 June 2022
episode14-big


More on this story...

Biotechnology
Prothena pens $1.2 billion deal with Novo Nordisk
12 July 2021
Biotechnology
Roche and Prothena move forward with PD drug prasinezumab
22 October 2020
Biotechnology
Roche's 10-year Alzheimer's study yields depressingly familiar result
16 June 2022
Pharmaceutical
Athira decimated by dismal Alzheimer's results
23 June 2022


Companies featured in this story

More ones to watch >


Today's issue

EU sets date for decision on proposed $16.5 billion Catalent buy
Pharmaceutical
EU sets date for decision on proposed $16.5 billion Catalent buy
5 November 2024
Pharmaceutical
AstraZeneca sees progress in obesity drug trials, highlights new oral option
5 November 2024
Biotechnology
Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Pharmaceutical
PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Pharmaceutical
Photocure’s Hexvix wins Chinese approval
5 November 2024
Pharmaceutical
Vertex ups guidance again as results exceed estimates
5 November 2024
Biotechnology
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024

Company Spotlight

A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.




More Features in Biotechnology

Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024
Frits van Alphen gets Memo CDO job
4 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze